Data as of Oct 31
| +1.79 / +1.61%|
Vertex Pharmaceuticals, Inc. is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs. The company's research focuses on cystic fibrosis; infectious diseases, including viral infections, such as influenza, and bacterial infections; autoimmune diseases, such as rheumatoid arthritis; cancer, inflammatory bowel disease; and neurological disorders, including pain, Huntington's disease and multiple sclerosis. Its product pipe line includes NCIVEK (telaprevir), which is marketed in the U.S. and Canada for the treatment of adults with genotype 1 hepatitis C virus, or HCV, infection; and KALYDECO (ivacaftor), which it markets in the U.S., Canada and Europe for the treatment of patients six years of age and older with cystic fibrosis, or CF, who have a specific genetic mutation that is referred to as the G551D mutation. The company's other drug candidates include ivacaftor, VX-809, VX-661, VX-135, VX-222, VX-509 and VX-787. Vertex Pharmaceuticals was founded by Boger S. Joshua in 1989 and is headquartered in Cambridge, MA.
|Jeff M. Leiden||Chairman, President & Chief Executive Officer|
|Ian F. Smith||Chief Financial Officer & Executive Vice President|
|Peter R. Mueller||Chief Scientific Officer|
|Jeffrey A. Chodakewitz||Chief Medical Officer & Senior Vice President|
|Kenneth L. Horton||Chief Legal Officer & Executive Vice President|